Edition:
United States

Profile: Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

6.96USD
22 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.96
Open
$6.93
Day's High
$7.04
Day's Low
$6.89
Volume
160,460
Avg. Vol
292,325
52-wk High
$11.71
52-wk Low
$4.61

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Company Address

Progenics Pharmaceuticals Inc

777 Old Saw Mill River Rd
TARRYTOWN   NY   10591-6717
P: +1914.7892800
F: +1914.7892817

Company Web Links